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Background: No previous studies have explored how closely women follow their psychotropic regimens during pregnancy. This study aimed to explore patterns of and factors associated with low adherence to psychotropic medication during pregnancy. 
Methods: Multinational web-based study performed in 18 countries in Europe, North America and Australia. Uniform data collection was ensured via an electronic questionnaire. Pregnant women were eligible to participate. Adherence was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8). The Beliefs About Prescribed Medicines Questionnaire (BMQ-specific), the Edinburgh Postnatal Depression Scale (EPDS), and a numeric rating scale were utilized to measure women´s beliefs, depressive symptoms and antidepressant risk perception, respectively. Participants reporting use of psychotropic medication during pregnancy (n=160) were included in the analysis.
Results: On the basis of the MMAS-8, 78 out of 160 women (48.8%, 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The rates of low adherence were 51.3% for medication for anxiety, 47.2% for depression, and 42.9% for other psychiatric disorders. Smoking during pregnancy, elevated antidepressant risk perception (risk≥6) and depressive symptoms were associated with a significant 3.9-fold, 2.3-fold and 2.5-fold increased likelihood of low medication adherence, respectively. Women on psychotropic polytherapy were less likely to demonstrate low adherence. The belief that the benefit of pharmacotherapy outweighed the risks positively correlated (r=0.282) with higher medication adherence. 
Conclusions: Approximately one out of two pregnant women using psychotropic medication demonstrated low adherence in pregnancy. Life-style factors, risk perception, depressive symptoms and individual beliefs are important factors related to adherence to psychotropic medication in pregnancy. 
Introduction
Psychiatric disorders, most commonly depression and anxiety, may develop among women of childbearing age1-3. Antenatal depressive and anxiety disorders, which are strongly coexistent, occur in as many as 13% and 8.5% of women, respectively2,4,5. Psychiatric disorders frequently require pharmacological treatment, even in pregnancy6. About 1-8% of women use antidepressants during pregnancy7-9, with selective serotonin reuptake inhibitors (SSRIs) being the preferred therapeutic choice for antenatal depressive and anxiety disorders3. Pharmacological treatment is however a special challenge among pregnant women since both effective treatment of the mother and prevention of harmful effects to the unborn child have to be assured.
Even though untreated depression or anxiety may pose harm to both mother and fetus and impair mother-child bonding10-12, women’s overestimation of the teratogenic risk of medication, fear of harming the unborn child and negative attitudes towards medication may negatively affect adherence to a needed pharmacotherapy13,14. Pregnancy has been described to be the driving factor for discontinuation of antidepressant therapy15, nevertheless, no previous studies have explored how closely pregnant women follow their psychotropic regimens in the context of ongoing use. Prior research has however indicated that overall 36-59% of women were poor adherers to their chronic regimens during pregnancy16,17.
Since medication discontinuation or suboptimal drug therapy of the underlying psychiatric disorder may lead to a relapse of the disorder over the course of the pregnancy and to adverse pregnancy outcomes10,11,18, more insight into the extent of and risk factors for low adherence during pregnancy is warranted.
This study aimed to investigate the level of adherence to psychotropic medication during pregnancy for treatment of depression, anxiety and other psychiatric disorders, and to explore whether maternal socio-demographics, mental health, women’s beliefs and risk perception are related to medication adherence during pregnancy. 
Materials and Methods
Study design and data collection
This is a multinational, cross-sectional, web-based study performed in 18 countries in Western, Northern and Eastern Europe, North America and Australia. Pregnant women at any gestational week were eligible to participate. Data were collected via an anonymous electronic questionnaire (http://www.questback.com (​http:​/​​/​www.questback.com​/​​)), accessible on-line for a period of two months in each participating country between 1-Oct-2011 and 29-Feb-2012. The complete questionnaire is presented elsewhere19. The questionnaire was open to the public via utilization of banners on national websites and/or social networks commonly visited by pregnant women. Websites were selected on the basis of the number of daily users. Information about recruitment tools utilized and internet penetration rates in each participating country are described in details elsewhere17. 
The questionnaire was first developed in Norwegian and English and then translated into other relevant languages. A pilot study in Finland, Italy, Norway and Sweden elicited no major changes. Data from the pilot study were not included in the analysis. Collected data were scrutinized for the presence of potential duplicates but none were identified. 
Psychotropic medication use 
Participants were presented with a list of chronic disorders including depression and anxiety. A free-text field was also available, where any other condition not previously listed could be specified. Women were then asked about medication use for each individual chronic disorder as free-text entry. All recorded medications were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes in accordance with the World Health Organization (WHO) ATC index20. Pregnant women reporting depression, anxiety, or other psychiatric disorders (i.e. bipolar, panic or personality disorders) were considered to be suffering from a psychotropic disorder and thus selected for the data analysis. Women reporting use of antidepressants (ATC N06A), antipsychotics (​http:​/​​/​www.whocc.no​/​atc_ddd_index​/​?code=N05A&showdescription=no​) (ATC N05A), anxiolytics (​http:​/​​/​www.whocc.no​/​atc_ddd_index​/​?code=N05B&showdescription=no​) (ATC N05B), hypnotics and sedatives (​http:​/​​/​www.whocc.no​/​atc_ddd_index​/​?code=N05C&showdescription=no​) (ATC N05C), antiepileptics (​http:​/​​/​www.whocc.no​/​atc_ddd_index​/​?code=N03A&showdescription=yes​) (ATC N03A) or sedating antihistamines (ATC R06A) for the treatment of any psychiatric disorder were classified as psychotropic medication users (Figure 1). 
Medication adherence 
Adherence to medication was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8)21. The MMAS-8 is a structured, self-reported medication adherence measure with a satisfactory internal consistency (Cronbach’s alpha reliability) of 0.8321-23. The MMAS-8 consists of seven yes/no items and one 5-point Likert scale. Each item measures specific medication-taking behavior, e.g. “problems remembering to take the medication”, “complexity of the therapeutic regimen”, “feeling hassled about sticking to the treatment plan”, “stopping the regimen because the medication make the patient feel worse”21. The predictive validity of the MMAS-8 has been examined through associations with blood pressure control among hypertensive patients (correct classification for high/medium adherence was 80.3%)21.The participants completed one MMAS-8 for each self-reported psychiatric disorder. Validated translated versions of the original English MMAS-8 were available in eight languages other than English. For the remaining six languages, translation into the relevant language and back-translation to English was done by two independent native speakers and/or translators. Prof. DE. Morisky approved the construct validity of all translated and/or adapted items of the MMAS-8 (Prof. DE. Morisky, personal e-mail communication).
For each disorder-specific MMAS-8, the sum score (range 0-8) was calculated and then trichotomized into low (sum score<6), medium (sum score 6 or 7) and high (sum score=8) adherence21. Imputed values were generated when respondents completed at least six of the eight items on the MMAS-8 (≥75% completion) using the estimation-maximization algorithm24. Values were imputed for 1.9% of the study population. 
Maternal socio-demographic and medical factors
Maternal socio-demographics included time of gestation, previous children, marital status, folic acid use before and/or during pregnancy, unplanned pregnancy, country of residency, age, employment status at time of conception, educational level, mother tongue, smoking status during pregnancy and alcohol consumption after awareness of pregnancy. Assessment of the study’s external validity was done by comparing socio-demographic and life-style characteristics of the sample on an individual country level with those of the general birthing population in the country, as described in detail elsewhere17. 
Maternal mental health was measured via the Edinburgh Postnatal Depression Scale (EPDS), a screening questionnaire for symptoms of depression during pregnancy and postpartum. The EPDS is a self-rating 10-item scale validated for major and minor depression in clinical settings and with satisfactorily Cronbach’s alpha reliability (0.87)25. Each question was scored 0-3, producing a total score of 0-30. The cut-off for probable depression was set to 1325. Validated translated versions of the original EPDS were available for eight languages other than English26. For the Serbian version, translation and back-translations were carried out by two independent linguistic experts and any discrepancies between the back-translated and original EPDS were settled. For the remaining five languages, we utilized translated versions used in previous studies27-30. 
Measurement of beliefs and risk perception
Women’s beliefs about medicines were explored via the Beliefs About Prescribed Medicines Questionnaire (BMQ-specific), which comprises two subscales: the BMQ-Necessity (5 items) and BMQ-Concerns (5 items)31,32. Respondents indicated their degree of agreement with each statement on a 5-point Likert scale (1=strongly disagree, 2=disagree, 3=uncertain, 4=agree, 5=strongly agree). Individual item scores were added, giving a total score of 5-25. Higher scores indicate stronger beliefs in the concepts represented by the subscale. The belief variables were used as continuous in the analysis. The Necessity-Concerns differential was also calculated. Validated versions of the translated BMQ-specific subscales were used whenever available31,33-38. For seven languages, translation of the original version and back-translation were carried out by two independent linguistic experts; any discrepancies between the back-translated and original version were settled. Imputed values were generated when respondents completed at least four of the five items on each subscale, using the estimation-maximization algorithm24. Values were imputed for 2.5% of the study population. 
Three statements were additionally used to explore women’s beliefs about medication use during pregnancy: i) “I have a higher threshold for using medicines when I am pregnant than when I am not pregnant”; ii) “Even though I am ill and could have taken medicines, it is better for the fetus that I refrain from using them”; iii) “Pregnant women should preferably use herbal remedies than conventional medicines”. Respondents could indicate their degree of agreement with each statement on a 5-point Likert scale (0=strongly disagree, 1=disagree, 2=uncertain, 3=agree, 4=strongly agree). The belief variables were used as continuous (score range 0-4) in the analysis. 
The perceived risk of antidepressant exposure during pregnancy was measured via a numeric scale ranging from 0 (‘not harmful to the fetus’) to 10 (‘very harmful to the fetus’). Exposure to antidepressants was not considered to increase the risk for congenital anomalies in the offspring (3-6%)39. 
Ethics
This study was carried out in compliance with the Helsinki Declaration. Informed consent was given by the participants by ticking the answer “yes” to the question “Are you willing to participate in the study?” Regional Ethics Committee in Norway, region Southeast, approved the study. Ethical approval or study notification to the relevant national Ethics Boards was achieved in specific countries as required by national legislation. All data were handled and stored anonymously. 
Statistical analysis
The Pearson chi-square and McNemar tests were used to compare proportions between independent and dependent groups, respectively. Student's t-test and one-way analysis of variance (​http:​/​​/​en.wikipedia.org​/​wiki​/​Analysis_of_variance" \o "Analysis of variance​) (ANOVA) with post-hoc testing (Bonferroni correction) were utilized to compare mean scores among two or more groups, respectively. The Spearman’s rank correlation coefficient was used to explore the correlation within the medication adherence sum scores and beliefs about medications. A p-value of <0.05 was considered statistically significant. 
Factors associated with medication adherence during pregnancy (dichotomous variable: low versus medium/high adherence) were explored via the Generalized Estimating Equations (GEE).40 The GEE was used to take into account clustering on region of residency. Data are presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). A two-tailed p-value of <0.05 was considered statistically significant. The multivariate GEE model was built as follows: candidate variables were selected based on a univariate p-value<0.15; variables having no role (p-value>0.05) or yielding a change smaller than 15% in the beta coefficients of the retained variables were removed; continuous variables were checked for linearity in the logit link. Because of non-linearity, the variable antidepressant risk perception was categorized according to the non-linearity midpoints (risk 0-3; 4-5; ≥6). The final multivariate model included statistically significant independent variables (smoking during pregnancy, number of psychotropic medications, EPDS score and antidepressant risk perception) and potential confounders (i.e. week of gestation, educational level and employment status). 
Internal consistency was assessed via reliability analysis41. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM® SPSS® Statistics). 
Results
Population characteristics
A total of 5,166 pregnant women accessed the electronic questionnaire and 5,095 (98.6%) completed it. Women with no eligible country of residency were excluded, leaving 4,938 participants. Among these, 262 (5.3%) pregnant women reported at least one psychiatric disorder and 163 of these reported use of psychotropic medications. Three out of 163 women did not fill the MMAS-8 (<75% completion) and were excluded from the analysis, leading to a final study population of 160 and 99 women reporting use and non-use, respectively, of psychotropic medications during pregnancy. Women with missing information in the MMAS-8 (<75% completion, n=3) were more often of immigrant status compared to women who did fill the MMAS-8 (66.7% vs. 4.4%; p=0.008). The mean gestational week at time of questionnaire completion was 20.9 (standard deviation: 10.5, range: 4-40). Data selection to achieve the final study sample is outlined in Figure 1.  
Of the 259 women with a psychiatric disorder, 160 (61.8%) reported treatment with psychotropic medications during pregnancy. Maternal characteristics and beliefs about medications according to medication use are shown in Tables 1 and 2, respectively. Most participants (200/259; 77.2%) were European residents, with 16.6% North American and 6.2% Australian residents, respectively. Women who used psychotropic medications differed significantly from non-users in region of residency, age, parity, alcohol use after awareness of pregnancy and pregnancy planning (Table 1). Women who did not use psychotropic medications most strongly believed that the necessity of medications did not outweigh their concerns and that despite being ill, it was better for the fetus to refrain from taking medications (Table 2). 
Antidepressants (mainly SSRIs) were the most commonly used medication group (144/259; 55.6%). Specific estimates of psychotropic medication use are outlined in Supplementary Table 1. The sample contained 53 women with concomitant psychiatric disorders, specifically depression/anxiety/other psychiatric disorders (n=4), depression/other psychiatric disorders (n=2) and depression/anxiety (n=47). The majority of participants using psychotropic medication (120/160, 75.0%) were on monotherapy, whereas 18.7%, 4.4% and 1.9% were treated with two, three or four psychotropic medications, respectively. 
Adherence 
Of the 160 psychotropic medication users, 78 (48.8%; 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The level of medication adherence by type of psychiatric disorder is outlined in Table 3. The rates of low adherence were 51.3% for anxiety, 47.2% for depression and 42.9% for other psychiatric disorders. In corollary analyses we observed no significant inter-disorder difference (chi-square test, p-value=0.392) in the rates of medication adherence among women concomitantly treated for depression (low: 42.6%; medium: 46.8%; high: 10.6%) and anxiety (low: 53.2%; medium: 38.3%; high: 8.5%). Among women treated for a single psychiatric disorder (n=107), no significant difference in the mean adherence sum score was found across the three disorder groups (mean scores for depression/anxiety/other psychiatric disorders: 5.54/5.58/6.03, respectively; ANOVA test, p=0.792). Also, the level of medication adherence did not significantly vary by trimester of pregnancy (mean scores for first/second/third trimester: 5.74/5.43/5.40, respectively; ANOVA test, p=0.624).
Factors associated with low adherence
In the multivariate analysis, smoking during pregnancy, psychotropic monotherapy, elevated risk perception of antidepressants and depressive symptoms during pregnancy were significantly associated with low adherence. The corresponding measures of association are shown in Table 4. 
The association between medication adherence and the BMQ-Necessity and BMQ-Concerns by type of psychiatric disorder is outlined in Table 5. Overall, there was a positive correlation between increasing level of adherence to psychotropic medication and perception that the benefit of pharmacotherapy outweighed the risks (r=0.282; p<0.001). 
Discussion
This is the first study to explore adherence to prescribed psychotropic medication in pregnancy using a validated instrument. The study is also novel in providing insight into the effect of pregnant women’s beliefs, perceptions of teratogenic risk and depressive symptoms on adherence to psychotropic medications during pregnancy. Several findings are important for clinical practice. First, many women did not adhere to psychotropic medication during pregnancy; this may raise concerns about suboptimal control of the underlying maternal psychiatric disorder. Second, understanding women’s beliefs about their psychotropic medications may assist clinicians in identifying women who are most likely to demonstrate low adherence. Third, knowledge that the most severely depressed women and those on psychotropic monotherapy are at greater risk of non-adherence may assist clinicians when following-up pregnant patients with psychiatric disorders. 
Of the women with psychiatric disorders included in the study, 61.8% were taking psychotropics, suggesting a significant psychiatric morbidity. This factor would however only affect the representativeness of the results pertaining to the total study population (including users and non-users of psychotropics), but not the comparison between these two groups or within the group of psychotropic medication users. The observed rates of low medication adherence during pregnancy were high across the different psychiatric disorders (42.9-51.3%). The results are however in line with prevalence estimates of non-adherence in the general population with psychiatric disorders (40-53%)42,43, but higher than what we previously found among women with somatic illness during pregnancy, using the same methodology17. The suboptimal treatment of psychiatric disorders in pregnant women is, however, of additional concern due to the potential risks of maternal-fetal health. Indeed, maternal depression during pregnancy may increase the risk of poor perinatal outcomes such as premature delivery, low birth weight and decreased breastfeeding initiation10,44. However, contradictory findings about the safety of antidepressants during pregnancy have so far posed significant challenges on practicing clinicians when assessing the risk of untreated depression versus the risk of pharmacotherapy45. 
In the current study we found that women’s beliefs about medications were a powerful determinant of low adherence. Women’s perception that the benefit of pharmacotherapy outweighed the risks and that herbal remedies should be preferred to conventional medications during pregnancy could in fact explain 28% and 26% of the variance in adherence to psychotropic medications, respectively. Since medication adherence represents a composite and multifaceted medication-taking behavior affected by several practical and perceptual factors, such correlation estimates can be deemed noteworthy and of importance in clinical settings. In the current study, elevated risk perception of antidepressants was associated with low medication adherence, possibly reflecting women’s fear that the needed medication might harm the fetus. Since pregnant women overestimate the risk of the medications they take and recall negative information far more often than reassuring information13,46, proper risk communication and information framing may represent effective tools in attenuating women’s negative beliefs and perceptions, thereby heightening medication adherence during pregnancy47,48. 
Among the risk factors explored, we found that maternal depression in pregnancy was associated with a significant 2.5-fold increased likelihood of low adherence to psychotropic medication during pregnancy compared to absence of depression. The lack of a temporal component in this cross-sectional study unfortunately impedes any substantiation of the relationship between low adherence to psychotropic medications and depressive symptoms, i.e. whether low adherence led to poorer mental health or the converse. In alignment with prior research in the general population49, we found that women on monotherapy demonstrated poorer adherence than those on polytherapy; a more severe or longer history of psychiatric disorders in the latter group, leading to better knowledge of the medications that are regularly taken, and not least higher awareness of the correct administration schedule could explain such a finding. Future research should test whether interventions proven to be effective in improving antidepressant adherence in the general population50 would be so also in the pregnant population.
Strengths and limitations
An important strength of the study is the use of a validated self-reported questionnaire of medication adherence, the MMAS-8. The internal consistency of the MMAS-8 was satisfactory among women treated for depression and other psychiatric disorders (Cronbach’s alpha ≥0.7), however it was borderline adequate for anxiety. Validated instruments with reliable psychometric properties were also utilized to measure women’s beliefs about medications and maternal mental health. With respect to the latter instrument, we used a cut-off score with high sensitivity and specificity in predicting probable depression26. Restriction to pregnant women only diminished the risk for recall bias. Data collection was conducted uniformly in all participating countries via utilization of an anonymous electronic questionnaire, which enabled us to potentially reach a large proportion of the birthing population. 
One limitation of the study is the lack of medically confirmed diagnoses. The psychiatric disorders were self-reported by the participants and hence dependent on the woman’s perception of the medical condition; the overall prevalence of psychiatric disorders observed in the current study might in fact be an underestimation of the true prevalence. We could however measure underlying maternal depression via the EPDS, which has been validated against clinical interview25, even though two measurements from each subject separated in time, would have been preferable 26. Information about medication use during pregnancy was also dependent on the accuracy of the woman’s reporting. The overall prevalence of low adherence is uncertain due to the small total study sample, but could nevertheless be estimated with a precision of ±8%. The study sample was also small for the individual psychiatric disorders, thus limiting the statistical power of specific sub-analyses. We did not have information about history of psychiatric disorders and prior treatments, ongoing non-pharmacological therapies, as well as the time of onset of the disorders, i.e. prior to or during pregnancy. Due to the small study sample, individual countries had to be combined into regions, thus restraining us from doing country-specific analyses on the relationship between beliefs and adherence. In a recent meta-analysis in a non-pregnant sample51, it was found that the association between patient’s beliefs and adherence seems to exist across different countries, languages and cultures. The questionnaire was only available through internet websites, which did not permit calculation of a conventional response rate. However, recent epidemiological studies indicate reasonable validity of web-based recruitment methods52,53. Also, the penetration rate of the internet, either in households or at work, is relatively high among women of childbearing age54-57. Hence, the degree to which our findings can be extrapolated to the target population is based on the representativeness of the respondents to the general birthing populations in each country. On average, the women in the study had higher education and were slightly more often primiparous than the general birthing populations in the various countries. Women with lower level of education might have been less likely to participate in the present study, whereas immigrant women more often did not complete the utilized adherence measure. These limitations should be borne in mind when considering the representativeness of the study. 
Conclusion
In our study we found that low adherence to psychotropic medication regimens is common during pregnancy, raising concern about suboptimal control of the underlying maternal psychiatric disorder. Individual beliefs and risk perception are important factors determining adherence to psychotropic medication in pregnancy. Adequate counseling and proper teratogenic risk communication will potentially attenuate women’s negative beliefs about medication and heighten medication adherence during pregnancy. Knowledge that women being prescribed psychotropic medications are at risk of non-adherence during pregnancy may assist clinicians when following-up pregnant patients with psychiatric disorders. 
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Table 1: Characteristics of the study population according to psychotropic medication use during pregnancy* (n=259)
Maternal Characteristics	Total study population(n=259)	Use of psychotropic medication  (n=160)	No use of psychotropic medication (n=99)	Use vs. no use of psychotropic medication 
	n (%)	n (%)	n (%)	p-value
Depressive symptoms‡NoYes	124 (49.8)125 (50.2)	78 (50.6)76 (49.4)	46 (48.4)49 (51.6)	0.733
EPDS score (mean ± sd)	12.8±5.9	12.5±6.0	13.3±5.6	0.288
Gestational week (mean ± sd)	21.1±10.4	20.9±10.5	21.4±10.5	0.729
Region of residency†Western EuropeNorthern EuropeEastern EuropeNorth AmericaAustralia	68 (26.3)106 (40.9)26 (10.0)43 (16.6)16 (6.2)	42 (26.2)70 (43.8)9 (5.6)25 (15.6)14 (8.8)	26 (26.3)36 (36.4)17 (17.2)18 (18.2)2 (2.0)	0.008
Maternal age (years)≤2021-30 ≥31	10 (3.9)132 (51.0)117 (45.2)	3 (1.9)71 (44.4)86 (53.8)	7 (7.1)61 (61.6)31 (31.3)	0.001
Previous children No Yes	129 (49.8)130 (50.2)	71 (44.4)89 (55.6)	58 (58.6)41 (41.4)	0.026
Marital status Married/cohabitingSingle/divorced/others	221 (85.3)38 (14.7)	137 (85.6)23 (14.4)	84 (84.8)15 (15.2)	0.864
Folic acid use§YesNo	241 (94.1)15 (5.9)	147 (93.0)11 (7.0)	94 (95.9)4 (4.1)	0.340
Working status Employed, but not as HCPHCPStudentHousewifeJob seekerOther than above	119 (58.8)34 (13.1)23 (8.9)36 (13.9)19 (7.3)28 (10.8)	70 (43.8)23 (14.4)15 (9.4)25 (15.6)11 (6.9)16 (10.0)	49 (49.5)11 (11.1)8 (8.1)11 (11.1)8 (8.1)12 (12.1)	0.803
Highest educational level Lower than high school High schoolHigher than high schoolOthers, unspecified	32 (12.4)73 (28.2)122 (47.1)32 (12.4)	20 (12.5)44 (27.5)77 (48.1)19 (11.9)	12 (12.1)29 (29.3)45 (45.5)13 (13.1)	0.970
Alcohol use after awareness of pregnancy NoYes	209 (80.7)50 (19.3)	121 (75.6)39 (24.4)	88 (88.9)11 (11.1)	0.009
Smoking before pregnancy NoYes	139 (53.9)119 (46.1)	87 (54.7)72 (45.3)	52 (52.5)47 (47.5)	0.731
Smoking during pregnancy NoYes	215 (83.3)43 (16.7)	130 (81.8)29 (18.2)	85 (85.9)14 (14.1)	0.390
Completely unplanned pregnancy YesNo	38 (14.7)220 (85.3)	29 (18.2)130 (81.8)	9 (9.1)90 (90.9)	0.044
Immigrant status**NoYes 	247 (95.4)12 (4.6)	153 (95.6)7 (4.4)	94 (94.9)5 (5.1)	0.802
Abbreviations: HCP=Health care provider; EPDS= Edinburgh Postnatal Depression Scale; sd=standard deviation. 
Statistically significant results (i.e. p-values <0.05) are presented in bold.
Numbers may not add up to total due to missing values (<4%). 

*Psychotropic medications include antidepressants, antipsychotics, anxiolytics, hypnotics and sedatives, antiepileptics and sedating antihistamines. 
‡Defined as having a score ≥13 on the Edinburgh Postnatal Depression Scale.
†Western Europe includes Austria, France, Italy, Switzerland, The Netherlands and United Kingdom; Northern Europe includes Finland, Iceland, Norway and Sweden; Eastern Europe includes Croatia, Poland, Russia, Serbia and Slovenia; North America includes USA and Canada. 
§Indicates folic acid use before and/or during pregnancy.
**Women having the first language different from the official main language in the country of residency.

Table 2: Beliefs about medications according to psychotropic medication use during pregnancy* (n=259)
	Total study population(n=259)	Use of psychotropic medication(n=160)	No use of psychotropic medication(n=99)	Use vs. no use of psychotropic medication
Beliefs about medication	Mean score ± sd	Mean score ± sd	Mean score ± sd	p-value
BMQ-specific‡				
Necessity	15.84 ± 5.55	17.36 ± 5.06	13.28 ± 5.42	<0.001
Concerns	13.95 ± 4.28	14.02 ± 3.96	13.85 ± 4.79	0.763
Necessity-Concerns differential	1.87 ±6.81	3.33 ± 6.71	-0.57 ± 6.28	<0.001
Pregnancy-specific beliefs†				
Statement 1	2.84 ± 1.45	2.79 ± 1.40	2.91 ± 1.53	0.539
Statement 2	2.63 ± 1.27	2.48 ± 1.24	2.87 ± 1.28	0.018
Statement 3	1.77 ± 1.24	1.70 ± 1.25	1.89 ± 1.21	0.238
Abbreviations: BMQ=Belief About Medicine Questionnaire; sd=standard deviation. 
Statistically significant results (i.e. p-values <0.05) are presented in bold. Missing values are <5%. 

*Psychotropic medications include antidepressants, antipsychotics, anxiolytics, hypnotics and sedatives, antiepileptics and sedating antihistamines. 
‡The BMQ-specific questionnaire comprises the BMQ-Necessity and BMQ-Concerns subscales (score range: 5-25). Higher scores indicate stronger beliefs in the concepts represented by the subscale. The Necessity-Concerns differential is the difference between the BMQ-Necessity and BMQ-Concerns scores (positive scores indicate that the patient perception of the benefits of medication outweigh the risks whereas a negative score indicates the converse). The BMQ-Specific is copyrighted (©Professor Robert Horne).
†Statement 1: “I have a higher threshold for using medicines when I am pregnant than when I am not pregnant”; Statement 2: “Even though I am ill and could have taken medicines, it is better for the foetus that I refrain from using them”; Statement 3: “Pregnant women should preferably use herbal remedies than conventional medicines”.




Table 3: Women’s level of adherence to psychotropic medications according to type of psychiatric disorder (n=160)
Psychiatric disorders	No. of subjects*	Cronbach's Alpha	Adherence Sum Score‡	Low adherence	Medium adherence	High adherence
	n		Mean ± sd	n (%)	n (%)	n (%)
Depression	127	0.73	5.51 ± 2.08	60 (47.2)	48 (37.8)	19 (15.0)
Anxiety	76	0.64	5.32 ± 1.92 	39 (51.3)	29 (38.2)	8 (10.5)
Other psychiatric disorders†	14	0.79	6.23 ± 2.07	6 (42.9)	2 (14.3)	6 (42.9)
Total 	160	-	5.52 ± 1.96	78 (48.8)	57 (35.6)	25 (15.6)
Abbreviations: MMAS-8=8-item Morisky Medication Adherence Scale; sd=standard deviation. 
Number of subjects exceeds 160 due to overlapping psychiatric disorders and related medication use. 

‡MMAS-8 sum score can range from 0 to 8.
†Other psychiatric disorders include bipolar disorder, panic disorder and personality disorders. 

Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A Licensure agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, dmorisky@ucla.edu (​mailto:dmorisky@ucla.edu​)

Table 4: Multivariate adjusted OR for low adherence to psychotropic medication* (n=160)
Variable	Adjusted OR (95% CI)	p-value
Smoking during pregnancyNoYes	Reference3.87 (1.86-8.02)	<0.001
Number of psychotropic medications=1>1	Reference0.32 (0.17-0.60)	<0.001
Depressive symptoms during pregnancy‡NoYes	Reference2.53 (1.37-4.67)	0.003
Antidepressant risk perception score0-34-5≥6	Reference1.28 (1.01-1.63)2.33 (1.38-3.93)	0.0450.001

*Smoking during pregnancy, number of psychotropic medication, symptoms of depression and antidepressant risk perception were the only significant independent variables retained in the final multivariate model. Adjustment was done for clustering on region of residency, educational level, employment status and gestational week.
‡Depressive symptoms were considered to be present whenever the EPDS score was ≥ 13.

Table 5: Correlation between beliefs about medications and adherence to psychotropic medications during pregnancy (n=160) 
	Medication adherence sum score (MMAS-8)
Beliefs about medication	Depression(n=127)	Anxiety(n=76)	Other psychiatric disorders(n=14)	Total(n=160)










Abbreviations: MMAS-8=8-item Morisky Medication Adherence Scale.
Statistically significant results (i.e. p-values <0.05) are presented in bold. *indicates p-values <0.05; ‡indicates p-values <0.01; §indicates p-values <0.001.
Number of subjects exceeds 160 due to overlapping psychiatric disorders and related medication use. 

The BMQ-specific questionnaire comprises the BMQ-Necessity and BMQ-Concerns subscales (score range: 5-25). Higher scores indicate stronger beliefs in the concepts represented by the subscale. The Necessity-Concerns differential is the difference between the BMQ-Necessity and BMQ-Concerns subscale (positive scores indicate that the patient perception of the benefits of medication outweigh the risks whereas a negative score indicates the converse). The BMQ-Specific is copyrighted (©Professor Robert Horne).

Statement 1: “I have a higher threshold for using medicines when I am pregnant than when I am not pregnant”; Statement 2: “Even though I am ill and could have taken medicines, it is better for the foetus that I refrain from using them”; Statement 3: “Pregnant women should preferably use herbal remedies than conventional medicines”.







*Psychiatric disorders include depression, anxiety and other psychiatric disorders (i.e. bipolar, panic and personality disorders).
‡MMAS-8 indicates the 8-item Morisky Medication Adherence Scale.
†Psychotropic medications include antidepressats, antipsychotics, anxiolytics, hypnotics and sedatives, antiepileptics and sedating antihistamines.
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